Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion-Reference-Cited by-全球学者库

Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion

Published:2023-05-23 Issue:2 Volume:6 Page:
ISSN:2096-5303
Container-title:Precision Clinical Medicine
language:en
Short-container-title:

Author:

Lei Yanna¹²,Zeng Shasha¹,Li Xiaoyu³²,Shu Pei³²,Wang Weiya⁴,Wang Yongsheng¹²^ORCID

Affiliation:

1. Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University , Chengdu 610041 , China

2. State Key Laboratory of Biotherapy, Sichuan University , Chengdu 610041 , China

3. Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University , Chengdu 610041 , China

4. Department of Pathology, West China Hospital, Sichuan University , Chengdu 610041 , China

Funder

National Natural Science Foundation of China

Natural and Science Foundation of Sichuan Province

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://academic.oup.com/pcm/advance-article-pdf/doi/10.1093/pcmedi/pbad011/50537751/pbad011.pdf

Reference10 articles.

1. Targeting ALK: Precision medicine takes on drug resistance;Lin;Cancer Discov,2017

2. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry;Mazieres;Ann Oncol,2019

3. Complex ALK fusions are associated with better prognosis in advanced non-small cell lung cancer;Kang;Front Oncol,2020

4. New perspectives for targeting therapy in ALK-positive human cancers;Zhao;Oncogene,2023

5. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis;Tao;Invest New Drugs,2022